Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), reported a series of transactions on June 17, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of 9,500 shares of common stock at an average price of $146.03 per share.
• Additionally, a total of 8,230 shares were sold in separate transactions at weighted average prices ranging from $548.13 to $555.91.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026.
• Following these transactions, Rothblatt beneficially owns 40,513 shares directly, with additional holdings reported indirectly through trusts and by a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves significant share sales by the CEO, the transactions are executed under a pre-established 10b5-1 plan, mitigating concerns about opportunistic selling based on non-public information.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and pre-determined approach to stock sales, which can mitigate insider trading concerns.
• The exercise of stock options and subsequent sale of shares suggests that the executive is realizing value from equity compensation, potentially indicating confidence in the company's past performance that led to option grants.

Negatives

• A significant number of shares were sold by a key executive, which could be interpreted negatively by the market, despite being part of a pre-planned strategy.
• The sale of shares at prices significantly higher than the exercise price of the options ($146.03) indicates a substantial gain for the executive, but also represents a reduction in their direct holdings.

Risks

• The ongoing 10b5-1 plan allows for continued sales until December 31, 2026, or until a large number of options are exercised, which could lead to further reductions in the executive's direct ownership over time.
• Market perception of significant insider selling, even under a 10b5-1 plan, can create downward pressure on the stock price.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, indicating potential for further transactions by the reporting person within this timeframe.

Management Comments

• The exercise of stock options and sale of resulting shares was pursuant to a pre-arranged 10b5-1 trading plan.
• The plan will continue until the earlier of the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a 10b5-1 plan by a CEO is common practice to diversify holdings or manage personal finances in a way that complies with insider trading regulations, especially in the biotechnology sector where stock price can be volatile.

Stakeholder Impact

• Shareholders: May perceive insider selling, even if pre-planned, as a negative signal, potentially impacting stock price in the short term. However, the structured nature of the sale under a 10b5-1 plan should limit concerns about adverse information.
• Employees: The executive's realization of value from stock options may not directly impact employees, but significant stock sales can influence overall employee morale if perceived negatively.
• Management: The transactions reflect standard executive compensation realization and portfolio management strategies.

Next Steps

• Continued execution of the 10b5-1 trading plan until its termination date (December 31, 2026) or completion of option exercises.
• Potential future filings of Form 4 to report any further transactions by Martine A. Rothblatt.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, 10b5-1 Plan, Martine A. Rothblatt, United Therapeutics Corp, UTHR, Beneficial Ownership, Stock Sale